GWM
AMRX icon

Gilpin Wealth Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Gilpin Wealth Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$121 Hold
6
– – ﹤0.01% 1262
2026
Q2 		$104 Buy
+6
New +$82 ﹤0.01% 1016

Other funds holding AMRX

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
SFGP
Stonebridge Financial Group (Pennsylvania) Wormleysburg, Pennsylvania $1.36B AUM 14.31% 1-Year Est. Return
VAG
VisionPoint Advisory Group Dallas, Texas $636M AUM 21.4% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
BONH
Bank of New Hampshire Laconia, New Hampshire $463M AUM 23.57% 1-Year Est. Return

Gilpin Wealth Management's AMRX Position: Q3 2026 in Review

Gilpin Wealth Management held its Amneal Pharmaceuticals (AMRX) position steady in Q3 2026 at 6 shares worth $121. The position accounts for ﹤0.01% of the portfolio, ranked #1262.

Gilpin Wealth Management first reported a position in AMRX in Q2 2026 and has held it in 2 quarters since. 14 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.

  • Gilpin Wealth Management held 6 shares of Amneal Pharmaceuticals worth $121 as of Q3 2026.
  • Gilpin Wealth Management left its Amneal Pharmaceuticals share count unchanged in Q3 2026.
  • Amneal Pharmaceuticals made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q3 2026, its #1262 holding.
  • Gilpin Wealth Management first reported a position in Amneal Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • 14 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.